Assertio Therapeutics Ownership
| ASRT Stock | USD 0.67 0.01 1.47% |
Assertio Stock Ownership Analysis
About 27.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.59. Some equities with similar Price to Book (P/B) outperform the market in the long run. Assertio Therapeutics has Price/Earnings To Growth (PEG) ratio of 1.5. The entity recorded a loss per share of 0.32. The firm had not issued any dividends in recent years. Assertio Therapeutics had 1:4 split on the 18th of May 2021. Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois. Assertio Holdings operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. For more info on Assertio Therapeutics please contact Brendan OGrady at 224 419 7106 or go to https://www.assertiotx.com.Assertio Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Assertio Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Assertio Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Assertio Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Assertio Therapeutics Outstanding Bonds
Assertio Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Assertio Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Assertio bonds can be classified according to their maturity, which is the date when Assertio Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.